All In Biotech

Drug Trial Radar · NCT04460066

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) Combined Albumin Binding Paclitaxel, Cisplatin in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma.

Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 18, 2020

Primary completion

Dec 6, 2021

Study completion Jul 15, 2023

Sponsor

Lead sponsor
Lee's Pharmaceutical LimitedIndustry
Sponsor type
Industry
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the safety and effect of anti-PD-L1 antibody (ZKAB001) in neoadjuvant chemotherapy of esophageal squamous carcinoma in combination with Alb-paclitaxel and cisplatin. The immunotherapy will be given before and after the operation every three weeks.

Conditions

  • Esophageal Cancer

Interventions

  • anti-PD-L1 antibodyDrug

    Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.

  • albumin bound paclitaxelDrug

    Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .

  • cisplatinDrug

    Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.

  • placeboDrug

    Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.

  • radical resection of esophageal carcinomaProcedure

    Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. major pathologic response rateTime frame: Two weeks after surgery.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.